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Abstract
Medication adherence is essential in preventing adverse intermediate outcomes, but little is known on hard outcomes. The aims of
this study were to determine the 1-year adherence to oral antihyperglycemic drugs (OADs) and to predict the risk of subsequent
health outcomes among (non)adherent patients with diabetes.
Using a large Swiss healthcare claims database from 2011 to 2014, we identiﬁed all patients aged ≥18 years with diabetes and
treated with at least 1 OAD prescription. Adherence to OADs was measured as the proportion of days covered (PDC) over 1 year
and subdivided into 2 categories: adherent (PDC≥80%), nonadherent (PDC<80%). We estimated the relative risk of hospitalization
and mortality at follow-up using multivariate Cox proportional hazard models.
Based on a sample of 26,713 patients, adherence to OADswas quite low: 42% of the patients achieved a PDC of≥80%during the
1-year observation period. A 7% reduction in the hospitalization risk and a 10% reduction in the risk of mortality could be observed in
adherent patients compared to nonadherent patients (hazard ratio [HR], 0.93 [95% CI, 0.89–0.97]; HR, 0.90 [95% CI, 0.82–0.99]).
Subgroup analysis showed that an intensiﬁed diabetes therapy had no signiﬁcant inﬂuence on the risk of both outcomes in adherent
patients.
Poor medication adherence increases the risk of subsequent hospitalizations and premature mortality in patient with diabetes,
regardless of disease severity and comorbidities. This emphasizes the need for an earlier identiﬁcation of patients with poor
medication adherence. The awareness of physicians and patients regarding the importance of adherence in diabetes treatment
should be increased.
Abbreviations: ATC = Anatomical Therapeutic Chemical, HbA1c = hemoglobin A1c, HR = hazard ratio, MPR = medication
possession rate, OAD = oral antihyperglycemic drug, PDC = proportion of days covered, WHO = World Health Organization.
Keywords: diabetes, hospitalization, medication adherence, mortality, oral antihyperglycemic drugs
1. Introduction
Medication adherence is considered as a key issue in the quality of
diabetes care. An appropriate pharmacotherapy is essential for an
effective diabetes management and in the meanwhile also driven
by a high awareness of physicians and other care providers.[1]
The beneﬁts of diabetes treatment adherence to intermediate
outcomes in patients with diabetes were investigated in several
empirical studies.[2] For example, previous research on anti-
hyperglycemic adherence primarily examined the association
between adherence and glycemic control, showing a signiﬁcantly
improved value of hemoglobin A1c (HbA1c) among patients
with high adherence.[3,4] In contrast, data on the impact of
medication adherence on further subsequent health outcomes are
relatively scarce. Some studies showed a reduced risk of
hospitalization, when patients continuously obtain oral anti-
hyperglycemic drugs (OADs).[5–7] There is also limited evidence
showing a beneﬁcial effect of diabetes medication adherence on
mortality, for example, in a US managed care setting, and on
healthcare costs, for example, among newly diagnosed Korean
patients.[8,9] Furthermore, existing ﬁndings on medication
adherence were based on outdated data, rather small sample
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sizes, and on data from Asian and US populations. Thus, it is
unclear whether the association is also given in a European
context. In addition, there is no standardized measurement of
adherence in a context of a wide range of adherence measures.[10]
One of the most commonly used method is the so-called
medication possession rate (MPR).[5,9,11,12] The MPR is a
method, which quantiﬁes medication adherence by summing
up the days’ supply for all prescribed drugs and afterwards by
dividing the number of days within the given observation period.
Since theMPR does not adjust for concurrently used drugs within
a medication class, the MPR tends to overestimate adherence. To
overcome this potential bias, recently published literature
recommend to calculate the proportion of days covered (PDC)
as a preferred method of measuring medication adherence, which
is a more conservative and precise instrument than the
MPR.[13,14] In this study, we aimed to apply the PDC, 1st to
determine the medication adherence in a large cohort of diabetes
patients receiving treatment with OADs, and 2nd to predict the
relative risk of hospitalization and mortality in adherent patients
compared to those who were not adherent.
2. Methods
2.1. Study design and population
We performed a retrospective cohort study using a large health
insurance claims database from January 1, 2011 to December 31,
2014. Claims data were derived from the leading health and
accident insurance company in Switzerland (Helsana Group),
which covers over 1 million Swiss mandatory insured persons.
The database comprises information on populations’ sociodemo-
graphics, type of health insurance, outpatient and inpatient
health care utilization, laboratory, and drug data. Drug data are
coded according to the World Health Organization (WHO)
Anatomical Therapeutic Chemical (ATC) Classiﬁcation System
and are based on all medications which were prescribed in the
outpatient setting and purchased directly by the dispending
physician or at the pharmacy.[15] Since the recorded claims cover
almost all health care invoices, these data are highly reliable. The
study population included continuously enrolled adult patients
who were diagnosed with a “glucose metabolism disorder
(diabetes mellitus)” or had at least 1 prescription of an
antihyperglycemic medication in the year before index date.
The index date was the 1st prescription of an oral antihyper-
glycemic medication during the recruiting period, which extends
to the 1st 3 years of the total study period (through December 31,
2013). After index date, patients had to be alive and continuously
enrolled for at least 1 year in order to obtain an appropriate
observation period for patients’ medication adherence. We also
excluded patients receiving any insulin prescription through the
period after index date. Eligible patients were afterwards
followed until the occurrence of the outcome, disenrollment,
death, or the end of the study (December 31, 2014). Figure 1
shows how patients with diabetes were selected for the cohort
study (ﬂowchart). According to the national ethical and legal
regulation, an ethical approval was not needed.
2.2. Medication adherence
Medication adherence to oral antihyperglycemic medication was
measured by PDC.[13,14] We calculated the PDC for each patient
as the number of days of medications supplied between the 1rst
prescription (x, index date) and the last date (y) of a 1-year
interval following the index date, divided by the total days of the
interval. The equation for the PDC is as follows:
PDC ¼ days supplied between x and y
365 days
 100%
We deﬁned the number of days supplied based on the deﬁned
daily doses for eachOAD class. The deﬁned daily dose reﬂects the
average daily dose for a drug used for its main indication in adults
Figure 1. This ﬂowchart provides an overview of the included patients.
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recommended by the WHO.[15] If days of supply added up to
more than 365 days, the supply was truncated at 365 days,
reﬂecting a maximum PDC of 100%. The PDC was based on
prescriptions for the following OAD classes according to the
WHO ATC Classiﬁcation System: biguanides (A10BA), sulfo-
namides (urea derivatives, A10BB), sulfonamides (heterocyclic,
A10BC), combinations of oral blood glucose lowering drugs
(A10BD), alpha glucosidase inhibitors (A10BF), thiazolidine-
diones (A10BG), dipeptidyl peptidase 4 inhibitors (A10BH),
other blood glucose lowering drugs, and excl. insulins (A10BX).
Patients receiving glucagon-like peptide-1 receptor agonists were
excluded. Since the different drug classes belong to 1 therapeutic
group and some patients with diabetes are recommended to take
2 or more OADs concurrently, we considered all classes
interchangeable. Patients were classiﬁed as adherent if their
individual PDC was ≥80%, respectively, as nonadherent with a
PDC of <80%, which is a recommended cut-off point in
literature.[16]
2.2.1. Outcomes and covariates. The outcome measures
included all-cause hospitalization and all-cause mortality during
the follow-up period (January 1, 2012 to December 31, 2014).
All-cause hospitalization was deﬁned as at least 1 overnight stay
in an acute-care hospital during patients’ follow-up period.
Several patient characteristics were included as covariates in the
regression models comprising age, sex, and health insurance plan
(managed care enrollment, high deductible class of>500 vs500
Swiss Francs), all measured at index date. Furthermore, we added
following 3 indicator variables for patients’ health status:
preceding hospitalization, number of comorbidities, and diabetes
drug therapy. Preceding hospitalization was deﬁned as an
overnight stay in an acute-care hospital in the year before index
date. Since national disease registers recording clinical diagnoses
are not available, we used prescription data to identify patients’
comorbidities in the year before index date. This approach is a
commonly used and well validated morbidity measure, which
indicates the occurrence of a broad range of (chronic)
diseases.[17,18] Additionally, we created a categorical variable
to indicate the intensity of diabetes drug therapy over 1 year after
index date by distinguishing between 3 different treatment
intensiﬁcations: metformin-only therapy, therapy with metfor-
min and another OAD, and therapy with other combinations of
OADs. The measurement of all 3 forms of diabetes therapy
relates to the summary of all prescribed OAD classes (according
to theWHOATCClassiﬁcation System) that we have recorded in
our database during the 1-year observation period of adherence
(1 year after index date).
2.3. Statistical analysis
We performed Chi-square tests and Kruskal–Wallis tests to
compare baseline characteristics between nonadherent patients
(PDC<80%) and adherent patients (PDC≥80%). In order to
display the distribution of the PDC, a density plot was provided
for the PDC (as continuous variable) for the nonadherent and the
adherent patient group. Multivariate Cox proportional hazards
regression models were used to estimate the relative risk of
medication adherence on hospitalization and mortality, control-
ling for age, sex, health insurance plan, preceding hospitalization,
number of comorbidities, and diabetes therapy. Hazard ratios
(HRs) together with the 95% conﬁdence intervals (95% CIs) are
presented. We performed the Cox regression models using the
PDC both as binary variable (PDC<80%/PDC≥80%) and as
continuous variable. All analyses were conducted using R version
3.2.0 (R Development Core Team 2015). A P-value <0.05 was
considered as statistically signiﬁcant.
3. Results
A total of 26,713 patients using OADs met the criteria for
inclusion. Table 1 reports the baseline characteristics for the total
studypopulation aswell as for the subdivided sample by adherence
status. Most of the total study population were men, had a
standard insurance health plan and a mean age of 69 years. The
most common therapy was metformin-only (41%). About a 3rd
was treated with metformin and another OAD (32%) and more
than a quarter received a therapy with other combinations of
OADs (27%). Almost 75% of the patients with diabetes suffered
from more than 1 comorbidity and nearly 10% had been
hospitalized 1 or more times during the year before index date.
The proportion of patients who were adherent to OAD therapy
was poor. Only 42% of the patients achieved a PDC of least 80%
during the 1 year observation period. The mean PDCwas 68% in
the total, 49% in the nonadherent and 94% in the adherent patient
group. As shown in the density plot of patients’ PDC (Figure 2), the
distribution of the PDC was continuously low among the
nonadherent patients, whereas the adherent patients had a high
proportion of those with a PDC>90%. When classiﬁed by the
adherence status, signiﬁcant differences could be observed in
almost all patient characteristics between adherent and non-
adherent patients. Comparedwith adherent patients, nonadherent
patients had statistically signiﬁcant more frequent a preceding
hospitalization, a slightly higher proportion of patients with at
least 5 comorbidities, and receivedmostlymetformin-only therapy
(P0.001). Half of the group of adherent patients had a more
intensiﬁed treatment with metformin and another OAD (50%).
Table 2 presents the adjusted risk for all-cause hospitalization.
We estimated a 7% reduction in the risk of hospitalization among
adherent patients compared to nonadherent patients (HR,
0.93 [95% CI, 0.89–0.97]), after adjustment for confounding.
Furthermore, the risk of hospitalization increased with age, the
number of comorbidities and the intensity of diabetes therapy.
Among nonadherent patients, receiving a diabetes therapy with
metformin and another OADwas associated with the highest risk
of hospitalization compared to other therapies (HR, 1.09 [95%
CI, 1.02–1.17]). In addition, the hospitalization risk increased
strongly when patients suffering from more than 4 comorbidities
(HR, 1.87 [95% CI, 1.72–2.02]). Adherent patients also had an
increased risk for hospitalization with an increased number of
comorbidities, but there was no signiﬁcant inﬂuence of the kind
of diabetes therapy.
As shown in Table 3, adherent patients had a 10% reduction in
the risk of mortality compared with nonadherent patients, after
adjustment for confounding (HR, 0.90 [95% CI, 0.82–0.99]).
Risk of mortality increased signiﬁcantly with age, intensity of
therapy, and number of comorbidities. Nonadherent patients had
an almost twice as high risk for death, when they were suffering
from multimorbidity with more than 4 concurrent conditions
(HR, 1.96 [95% CI, 1.66–2.32]). This association is slightly
weaker with an HR of 1.83 (95% CI, 1.50–2.24) in the adherent
patient group. Whereas the therapy intensity had no signiﬁcant
inﬂuence on the mortality risk in adherent patients, the 2
combined OAD therapies increased the risk for almost a quarter
with an HR of 1.23 (95% CI, 1.06–1.41) and 1.24 (95% CI,
1.10–1.40) in the nonadherent patients. Additional analyses, in
which we used the PDC as continuous variable, conﬁrmed the
positive effect of medication adherence on patients’ hospitaliza-
Huber et al. Medicine (2016) 95:26 www.md-journal.com
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tion and mortality risk among the total and the nonadherent
patient group (Table S1, Table S2, http://links.lww.com/MD/
B61). We could not observe a signiﬁcant effect on both outcomes
in the adherent group.
4. Discussion
The main ﬁnding of this study was that adherence to
antihyperglycemic medication is signiﬁcantly associated with a
7% decrease in risk of hospitalization and a 10% reduction in
mortality risk compared with nonadherence in patients with
diabetes. This ﬁnding is in line with the limited previous research
showing improved intermediate outcomes due to better adher-
ence to drug therapy in patients with diabetes. For example, a
systematic review revealed that high adherence was associated
with improved glycemic control in patients with diabetes.[2] But
as this review summarized, previous work mainly focused on the
Table 1
Patient characteristics at baseline by medication adherence.
Total Nonadherent patients (PDC80) Adherent patients (PDC≥80)
Variable n % n % n % P
Population 26,713 100.0 15,399 57.6 11,314 42.4
Gender 0.01
Male 14,337 53.7 7985 51.9 6352 56.1
Female 12,376 46.3 7414 48.1 4962 43.9
Mean age (years [SD]) 69.0 (11.9) 68.8 (12.4) 69.4 (11.0) 0.07
Age in groups 0.01
18–44 751 2.8 562 3.6 189 1.7
45–54 2421 9.1 1470 9.5 951 8.4
55–64 5633 21.1 3216 20.9 2417 21.4
65–74 8381 31.4 4602 29.9 3779 33.4
75–84 7396 27.7 4216 27.4 3180 28.1
≥85 2131 8.0 1333 8.7 798 7.1
Insurance plan
Managed care 8011 30.0 4652 30.2 3359 29.7 0.37
High deductible class (>500 Swiss Francs) 1439 5.4 961 6.2 478 4.2 0.01
Preceding hospitalization 2549 9.2 1677 10.9 872 7.7 0.01
Diabetes therapy 0.01
Metformin only 11,035 41.3 9181 59.6 1854 16.4
Metformin+another OAD 8551 32.0 2875 18.7 5676 50.2
Other combinations of OADs 7126 26.7 3343 21.7 3784 33.4
PDC 0.01
Mean PDC (SD) 67.9 (26.9) 49.0 (19.7) 93.5 (6.4)
Median PDC (IQR) 72.8 (44.5) 50.3 (31.9) 95.1 (11.8)
Number of comorbidities 0.01
0–1 6817 25.5 4097 26.6 2720 24.0
2–4 15,041 56.3 8438 54.8 6603 58.4
≥5 4855 18.2 2864 18.6 1991 17.6
IQR= inter-quartile range, OAD= oral antihyperglycemic drug, PDC=proportion of days covered, SD= standard deviation.
Figure 2. This ﬁgure displays two density plots.
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Table 2
Cox proportional hazard analysis of all-cause hospitalization and PDC (<80%/≥80%).
Hospitalization risk
Total Nonadherent patients (PDC<80%) Adherent patients (PDC≥80%)
Variable Hazard ratio (95% CI) P Hazard ratio (95% CI) P Hazard ratio (95% CI) P
Gender
Male 1.00 1.00 1.00
Female 0.88 (0.84–0.91) 0.001 0.92 (0.88–0.97) 0.01 0.82 (0.77–0.87) 0.01
Age in groups
18–44 1.00 1.00 1.00
45–54 0.997 (0.84–1.19) 0.975 1.01 (0.82–1.24) 0.016 1.02 (0.73–1.42) 0.923
55–64 1.30 (1.10–1.53) 0.01 1.27 (1.05–1.54) 0.001 1.38 (1.01–1.90) 0.05
65–74 1.75 (1.49–2.06) 0.001 1.69 (1.40–2.04) 0.001 1.90 (1.40–2.60) 0.01
75–84 2.32 (1.98–2.73) 0.001 2.30 (1.91–2.77) 0.001 2.45 (1.80–3.34) 0.01
≥85 2.65 (2.24–3.13) 0.001 2.51 (2.06–3.06) 0.001 2.98 (2.16–4.10) 0.01
Insurance plan
Managed care 0.96 (0.92–1.002) 0.059 0.95 (0.90–1.01) 0.081 0.97 (0.91–1.03) 0.334
High deductible class (>500 Swiss Francs) 0.79 (0.71–0.87) 0.001 0.79 (0.69–0.89) 0.001 0.80 (0.68–0.95) 0.01
Preceding hospitalization 1.49 (1.41–1.58) 0.001 1.51 (1.41–1.63) 0.001 1.45 (1.32–1.60) 0.01
High adherence (PDC≥80) 0.93 (0.89–0.97) 0.001
Diabetes therapy
Metformin only 1.00 1.00 1.00
Metformin and another OAD 1.05 (1.003–1.11) 0.05 1.09 (1.02–1.17) 0.01 1.03 (0.95–1.12) 0.516
Other combination of OADs 1.07 (1.02–1.12) 0.01 1.05 (0.98–1.11) 0.142 1.08 (0.99–1.18) 0.10
Number of comorbidities
0–1 1.00 1.00 1.00
2–4 1.28 (1.21–1.34) 0.001 1.29 (1.21–1.38) 0.001 1.25 (1.16–1.36) 0.01
≥5 1.83 (1.73–1.95) 0.001 1.87 (1.73–2.02) 0.001 1.78 (1.62–1.95) 0.01
95% CI=95% conﬁdence interval, OAD= oral antihyperglycemic drug, PDC=proportion of days covered.
Table 3
Cox proportional hazard analysis of all-cause mortality and PDC (<80%/≥80%).
Mortality risk
Total Nonadherent patients (PDC<80%) Adherent patients (PDC≥80%)
Variable Hazard ratio (95% CI) P Hazard ratio (95% CI) P Hazard ratio (95% CI) P
Gender
Male 1.00 1.00 1.00
Female 0.69 (0.63–0.74) 0.001 0.76 (0.68–0.85) 0.001 0.59 (0.52–0.68) 0.01
Age in groups
18–44 1.00 1.00 1.00
45–54 3.61 (0.86–15.17) 0.080 5.60 (0.75–42.10) 0.094 1.82 (0.23–14.25) 0.567
55–64 7.73 (1.91–31.24) 0.01 9.72 (1.35–70.06) 0.05 5.06 (0.70–36.43) 0.108
65–74 16.23 (4.04–65.13) 0.001 21.92 (3.07–156.41) 0.01 9.85 (1.38–70.31) 0.05
75–84 49.06 (12.25–196.55) 0.001 72.17 (10.14–513.55) 0.001 27.09 (3.81–192.84) 0.01
≥85 142.28 (35.50–570.31) 0.001 201.09 (28.24–1431.68) 0.001 83.09 (11.65–592.37) 0.01
Insurance plan
Managed care 0.86 (0.77–0.94) 0.01 0.85 (0.75–0.97) 0.05 0.86 (0.74–0.99) 0.05
High deductible class (>500 Swiss Francs) 0.86 (0.68–1.07) 0.169 0.83 (0.63–1.10) 0.194 0.92 (0.64–1.33) 0.671
Preceding hospitalization 1.45 (1.29–1.63) 0.001 1.42 (1.23–1.65) 0.001 1.50 (1.24–1.82) 0.01
High adherence (PDC≥80) 0.90 (0.82–0.99) 0.05
Diabetes therapy
Metformin only 1.00 1.00 1.00
Metformin and another OAD 1.18 (1.06–1.31) 0.01 1.23 (1.06–1.41) 0.01 1.05 (0.87–1.27) 0.601
Other combination of OAD 1.18 (1.07–1.31) 0.01 1.24 (1.10–1.40) 0.001 1.04 (0.85–1.26) 0.736
Number of comorbidities
0–1 1.00 1.00
2–4 1.24 (1.10–1.39) 0.001 1.25 (1.07–1.45) 0.01 1.22 (1.02–1.46) 0.05
≥5 1.92 (1.69–2.18) 0.001 1.96 (1.66–2.32) 0.001 1.83 (1.50–2.24) 0.01
95% CI=95% conﬁdence interval, OAD= oral antihyperglycemic drug, PDC=proportion of days covered.
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association between adherence and intermediate outcomes.
However, there is some evidence for the beneﬁcial effect of
medication adherence on further important patient outcomes.
For example, Sokol et al[6] could show that high levels of
medication adherence (measured as adherence rates) were
associated with lower disease-related medical costs and hospital-
ization rates. Some further studies also revealed that non-
adherence to antihyperglycemic medication (measured as MPR)
leads to an increased risk of hospitalization, health care costs, and
mortality.[5,9] However, it is difﬁcult to compare our ﬁndings
with those from existing work, which was based on varying
measures of adherence, rather outdated data, or on subpopu-
lations including only newly treated patients. Therefore, the
present study expands the existing literature on medication
adherence in patients with diabetes and highlights the importance
of the adherence to oral hyperglycemic medication regarding
avoidable adverse patient outcomes such as hospitalization and
premature mortality.
The analysis of subgroups revealed 3 further important
ﬁndings: ﬁrst of all, when we used the PDC as continuous
variable and performed subgroup analysis for the nonadherent
and the adherent patient group, we could also observe that the
effect of the PDC is meaningful on the patient outcomes. The
lower the PDC the higher the risk among nonadherent patients. In
contrast, among patients who were already in the adherent
group, an increase of the PDC did not further inﬂuence the
hospitalization and mortality risk. Second, we could prove that
the beneﬁt of adherence remains with the increase of the
complexity of the diabetes therapy, since the group with
additional diabetes drugs (most likely reﬂecting disease severity)
showed a lower risk of hospitalization as well as a reduced risk of
mortality. In this context, the Action to Control Cardiovascular
Risk in Diabetes trial has been discussed often if intensiﬁed
diabetes treatment may have harmful effects due to side effects of
the drugs or increased number of hypoglycemic events.[19]
However, even we have no HbA1c levels and cannot conclude on
the glycemic control, we can state that we could not observe any
evidence showing negative effects of the escalation of the
medication. The third important subgroup ﬁnding was, that
even with additional diseases, patients take advantage of
adherence, since these patients also showed a signiﬁcantly
reduced risk of hospitalization and mortality compared to
nonadherent patients. Multimorbidity is often regarded as a
reason for negative drug effects and as reasoning for depres-
cription, especially among elderly patients.[20] Our results
contribute to this discussion at least in a way that adherence is
beneﬁcial even in multimorbidity.
Besides the main ﬁnding of our study, the study also revealed
that the medication adherence in patients with diabetes was quite
low. Only 42% of the patients were adherent (≥80% PDC) to
OAD therapy during the 1 year observation period. This result is
in line with the lowest value from ﬁndings of 2 systematic reviews
on adherence to diabetes medication, which reported an
adherence rate ranging from approximately 40% to
90%.[21,22] Furthermore, we could observe that the PDC was
continuously quite low in the nonadherent patient group, but the
proportion of the adherent patients with a PDC with >90% was
high. Whereas we found the highest proportion of nonadherent
patients in patients using metformin only, most adherent patients
were treated with combinations of OADs (metformin and
another OAD, other combinations of OADs). This is conﬂicting
with previous work, which showed a higher proportion of
adherent patients than in nonadherent patients in users of oral
hypoglycemic only.[8] However, comparing results is challenging
due to the small amount of evidence available, which investigated
this association. Moreover, it is difﬁcult to compare adherence
rates with each other, since the study design, the included
populations, the used medications classes, and especially the
applied measurement of adherence can completely differ between
the studies. According to the current literature, the PDC is the
recommended instrument to measure medication adherence,
which provides rather conservative estimates and accounts for
clinical situations when patients switch drugs or use multiple
medications concurrently.[10,13] Thus, we stress the need for the
introduction of a standardized measure of medication adherence
such as the PDC in future studies on diabetes care.
Some strengths and limitations of our study have to be
acknowledged. The major strength of our study is that it is, to the
best of our knowledge, the ﬁrst study investigating the impact of
adherence to diabetes medication on hospitalization and
mortality in Europe. Another strength is that the ﬁndings were
based on a comprehensive dataset including a large amount of
patients treated in primary care. Furthermore, we included a real-
life patient sample, comprising both elderly and nonelderly
patients, and did not exclude subpopulations as it is used most
often in randomized control trials (e.g., patients aged over 65
years and older, or those without comorbidity). Additionally, we
applied the most recent and recommended adherence measure-
ment, which allows a more realistic estimate of medication
adherence than previously usedmeasurements, and thus avoiding
overestimation. Our study has also limitations. First of all, there
might be a bias regarding identiﬁcation of patients with diabetes,
since we could not include patients who receive only lifestyle
treatment. Furthermore, we measured adherence by the PDC,
which might be a good measure, but in the end does not reﬂect
real intake of the drugs. A further weakness is that we did not
have any clinical parameters as diabetes duration, but also no
laboratory data as, for example, the HbA1c level. So, we could
not conclude from adherence to glycemic control.
In conclusion, poor medication adherence increases the risk of
subsequent hospitalizations and premature mortality in patient
with diabetes, regardless of disease severity and comorbidities.
This has a high clinical impact and emphasizes the need for an
earlier identiﬁcation of patients with poor medication adherence.
The awareness of physicians as well as patients regarding the
importance of adherence in diabetes treatment should be
increased.
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